The Fastest Path to Commercial Insights

Helping life sciences teams make complex asset and portfolio choices to sharpen pipeline strategy

Get fresh primary market research-driven insights and answers to your most pressing business questions in 15 days or less

Contact our experts

ACCELERATE CONFIDENT DECISIONS

Meet tight deadlines and budget constraints with rapid, high-quality insights that keep pipeline planning on track. We help pharma teams:

  • Get fundamental market understanding
  • Define winning TPPs

  • Prioritize the right diseases
  • Develop a business case for an asset
  • Get external validation
Let’s Meet

THE SMARTER 4TH OPTION

On-demand commercial assessments in 4 weeks – easier than DIY, sharper than syndicated, faster than consulting

See what our clients are saying

INSIGHTS GROUNDED IN PRIMARY RESEARCH

Tailored, on-demand reports built from fresh KOL input to answer your toughest questions

Our Solutions

Disease Market Assessment

Understand current and future market landscape

TPP Development & Testing

Define and test product profiles with KOL and/or payer input

Indication Prioritization

Rank commercial opportunities across diseases

Two ways to access insights

Schedule a demo

WHERE OTHERS HESITATE, WE SPECIALIZE

Bringing clarity to the most complex and underserved markets, delivering insights that de-risk decisions and improve business cases.

200+

Diseases covered

14

Therapy areas

RARE DISEASES

ONCOLOGY

NICHE SUBPOPULATIONS

OUR RESEARCH MODEL

Lead by senior experts. Uncompromising quality.

ON-DEMAND

Fresh market research is conducted upon request for any disease

FAST

New research and insights delivered in 4 weeks

PMR-DRIVEN

Insights informed by qualitative interviews and/or quantitative surveys

SENIOR TEAM

Experienced team members (10+ years in pharma market research) conduct the research

CUSTOMIZABLE

Research tailored to your questions and topics

Meet our senior team

HOW IT WORKS

From order to insights

GET AN INSTANT QUOTE

HOW IT WORKS

From order to insights

GET AN INSTANT QUOTE

WHAT OUR CLIENTS ARE SAYING

It was great to see you at your market access pulse survey readout on Wednesday! The team’s feedback has been consistently very positive with the product quality, Melissa’s expertise, and the process getting the research completed on time. I’m so glad that [name] has you as an obvious go-to-choice for ad hoc requests for [our product].

Sr. Manager, Commercial Analytics

For us, MarketVue® is very valuable to get fast reports and at the right level of detail. We were originally supposed to develop disease strategies but then we had a reorganization and resources were constrained. REACH is a great help to us.

Konstanze Binder

Principal, Global Asset Maximization · LEO Pharma

I need something beyond what I can do for myself with Google and without paying an extraordinary amount of money… MarketVue® goes even further — it’s not your typical syndicated report. It was very collaborative. REACH operates with the best aspects of primary research but then benefits like speed of syndicated reports.

Tony Russell

Director, Commercial Development · Pfizer

With MarketVue® reports, you can get 80-90% of output for 10% of the cost [of custom consulting] — this is great, especially for small clients like us whose budgets are tight, and we don’t have a ton of FTEs. I’m a team of 1. I can’t blow my whole budget on a single question.

Joe Pirrello

Executive Director, Business Development · Astria Therapeutics

Regarding the [rare disease] development program related to our project before the break, I don’t recall if I ever relayed the message – folks were very complimentary of the supportive market research, so THANK YOU very much for a very successful and timely engagement. Let’s stay in touch over the coming weeks on any imminent projects that may materialize on our end.

Director, New Product Commercialization

Before even getting to the MarketVue® product, the process is a huge plus for them. The fact that we can get a tailored report with essentially a proprietary set of questions at that price range with that level of engagement with the team is hugely valuable and gives us a lot of trust with what we receive. MarketVue® is really high quality in general and comparable to much more expensive reports where you get a 100-page report — in terms of value for the amount we use it, it is comparable to much, much more expensive research… They’re really good at highlighting what is most relevant.

Julia Chornak

Senior Manager, Market Insights · Chinook Therapeutics

BTW – I wanted to tell you that the chatter with the [rapid insights] work you just delivered within our NPC team is that you killed it. So, I anticipate you will be our go to for much more work like this in the future.

Director, Pipeline/New Product Commercialization

REACH reports give you the ability to tailor the research a little bit more. I work in rare disease where [syndicated reports] just don’t exist and if they do, they’re not built out. For folks like myself, there is limited ability to use those off-the-shelf reports since they’re focused on mass market. I value the REACH team’s ability and willingness to answer follow up questions, dive in around specific topics, push back on the report, and think critically with us around the implications of the findings… I eventually asked them to synthesize all of our email back/forth into a separate report because I thought it was so useful and thoughtful.

Joe Pirrello

Executive Director, Business Development · Astria Therapeutics

What pushed me over the edge was that they have a nice way of presenting the findings in the end. Sometimes you get a wall of text. Their output was very clean and useful for putting into our slides. I’ve worked with a lot of vendors, and it can be pretty hit or miss. Some vendors can be good at executing, but REACH can be a thought partner. They can take what we’re saying and riff off of us, then come up with additional ideas and put them in front of us.

Kathleen Davenport

Senior Director, New Product Planning · Surface Oncology

Meet with our experts

REACH out to our experts or subscribe to our complementary newsletter on rare and niche disease drug development strategy.

CONTACT US
SUBSCRIBE NOW